X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. It is being evaluated for the treatment of episodic and chronic migraine.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
The proceeds will be used to support the late-stage clinical development of ABP-450, which contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum, being developed for the treatment of episodic migraine.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Daewoong Pharmaceutical
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 19, 2024
Details:
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. It is being evaluated for the treatment of episodic and chronic migraine.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. AEON recently completed Phase 2 of ABP-450 for cervical dystonia and has an ongoing Phase 2 of ABP-450 for both chronic and episodic migraine.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
The combined company will focus on the development of ABP-450 (prabotulinumtoxinA) injection, the same botulinum toxin approved and marketed for an aesthetic indication, to treat debilitating medical conditions in neurology.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Priveterra Acquisition Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger July 21, 2023
Details:
The combined company will focus on the development of ABP-450 (prabotulinumtoxinA) injection, the same botulinum toxin approved and marketed for an aesthetic indication, to treat debilitating medical conditions in neurology.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Priveterra Acquisition Corp.
Deal Size: $276.0 million Upfront Cash: $276.0 million
Deal Type: Merger July 11, 2023
Details:
The net funding will be used in the development of ABP-450 (prabotulinumtoxinA) which contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum, for the preventive treatment of episodic migraine.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 30, 2023
Details:
ABP-450 (prabotulinumtoxinA) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine thereby leading to denervation of the muscle and a flaccid paralysis.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. AEON recently completed Phase 2 of ABP-450 for cervical dystonia and has an ongoing Phase 2 of ABP-450 for both chronic and episodic migraine.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 10, 2023
Details:
ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins.
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
